FINWIRES · TerminalLIVE
FINWIRES

Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating

By

Related Articles

Research

Calian Group Price Targets Raised at RBC, Desjardins

Analysts at RBC Capital Markets and Desjardins raised their price targets on Calian Group Ltd. (CGY.TO) to $90 from $78, and to $90 from $83, respectively.RBC analyst Paul Treiber maintained an Outperform rating on shares of the Canadian diverse products and services company following its quarterly results.The stock rose $14.24, or 20.9%, to $82.24 on the Toronto Stock Exchange."Calian reported a solid quarter, with revenue, adj. EBITDA, and adj. EPS all above RBC/consensus," Treiber said in a note to clients."Organic growth strengthened and bookings were strong, primarily due to increasing demand from defence customers, along with a recovery in US commercial," the analyst said.We believe acquisitions in the defence segment are potential catalysts for the stock," Treiber said.Desjardins analyst Benoit Poirier maintained a Buy rating on Calian."This quarter marked an important inflection in CGY's defence business after months of newsflow and questions we are now actually starting to see tangible execution/bookings from increased budgets/ spending in both Canada and Europe," Poirier said in a note to clients."...With the stock now trading at a premium to its five-year average, potential acquisitions will become even more accretive," the analyst said.

$CGY.TO
Research

Stephens Upgrades Aveanna Healthcare to Overweight From Equalweight, Adjusts Price Target to $11 From $10

Aveanna Healthcare Holdings Inc (AVAH) has an average rating of overweight and mean price target of $9.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AVAH
Research

JPMorgan Upgrades Timken to Neutral From Underweight, Adjusts Price Target to $130 From $110

Timken (TKR) has an average rating of overweight and mean price target of $130, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TKR